Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) fell 3.2% on Thursday . The stock traded as low as $13.11 and last traded at $13.14, with a volume of 134,302 shares traded. The stock had previously closed at $13.57.

Several brokerages have weighed in on PRTK. Robert W. Baird began coverage on Paratek Pharmaceuticals in a research report on Friday, May 13th. They set an “outperform” rating and a $30.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Monday, May 16th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, May 4th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Finally, Ladenburg Thalmann increased their price target on Paratek Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, June 17th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $35.88.

The firm’s market cap is $302.07 million. The company’s 50 day moving average price is $13.07 and its 200-day moving average price is $14.32.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.03.

In other news, major shareholder Fund Iv L.P. Omega acquired 461,538 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average price of $13.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Bigham acquired 20,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Thursday, June 23rd. The shares were purchased at an average cost of $13.45 per share, for a total transaction of $269,000.00. Following the purchase, the chief executive officer now directly owns 100,000 shares of the company’s stock, valued at approximately $1,345,000. The disclosure for this purchase can be found here.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.